Michael Cloonan, M.B.A., is the Chief Executive Officer of Sionna Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to developing novel small molecule therapies for cystic fibrosis (CF) and other anion channelopathies. With over 25 years of experience in the biotechnology and pharmaceutical industries, Cloonan has built a distinguished career leading financial strategy, business development, and operational growth for innovative companies. He holds an M.B.A. from Babson College and a B.S. in Finance from Northeastern University, equipping him with deep expertise in capital markets and strategic leadership. Prior to joining Sionna in 2023, Cloonan served as Chief Financial Officer at bluebird bio, inc., where he oversaw the company's public listing on Nasdaq, raised over $500 million in equity financing, and navigated complex gene therapy development challenges amid rapid expansion. Earlier roles included Vice President of Finance at Cubist Pharmaceuticals, which was acquired by Merck for $8.4 billion in 2014, and senior finance positions at Genzyme Corporation (now part of Sanofi). His achievements encompass successful IPOs, strategic partnerships, and M&A transactions that have accelerated pipeline advancement and delivered substantial shareholder value. As CEO of Sionna Therapeutics, Cloonan drives the company's mission to address unmet needs in CF by advancing its proprietary SION-switch platform and lead candidates like SION-109 and SION-638 through clinical development. Under his leadership, Sionna has secured significant venture funding exceeding $200 million, forged key collaborations, and progressed toward pivotal trials, positioning the company as a frontrunner in next-generation CFTR modulators. Cloonan's strategic vision continues to propel Sionna's growth, blending rigorous science with disciplined execution to bring transformative therapies to patients.